In the previous issue of Critical Care, Su and colleagues [1] reported on the usefulness of measuring urinary concentrations of the soluble form of the triggering receptor expressed on myeloid cells-1 (sTREM-1) during sepsis. One hundred four patients were enrolled in the authors' study: 16 presented with systemic infl ammatory response syndrome, 35 with sepsis, and 53 with severe sepsis/septic shock.
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Th e authors demonstrated that the urinary sTREM-1 concentration was associated with the positive diagnosis of sepsis with an acceptable area under the receiver operat ing characteristic curve (0.797, 95% confi dence interval 0.711 to 0.884). TREM-1 is a member of the immuno globulin superfamily expressed mainly on mature monocytes, macrophages, and neutrophils. Its engagement leads to an amplifi cation of the infl ammatory response mediated by the activation of Toll-like and NOD-like receptors [1, 2] . A soluble form of TREM-1 appears after its cleavage from the cell's surface through the action of matrix metalloprotease-9 [3] . sTREM-1 has been studied as a sepsis biomarker, but investigations of its plasma concentration have had contrasting results. Indeed, a recent meta-analysis showed an 82% sensitivity and an 86% specifi city in this setting [4] . All in all, plasma sTREM-1 proved to be equivalent to procalcitonin in diagnosing sepsis. More interesting is the fact that the evaluation of local produc tion of sTREM-1, at the site of presumed infection, is associated with better perfor mances: this has been studied during pneumonia, arthritis, pancreatitis, perito nitis, and meningitis [5] [6] [7] [8] [9] .
In the study by Su and colleagues, the urinary sTREM-1 concentration was able to predict sepsis with a good specifi city (93%) but a modest sensitivity (64%). Th is low sensitivity may be explained by the fact that urinary sTREM-1 measurement has been found to be inaccurate for the diagnosis of urinary sepsis [10] : about 30% of the patients reported by Su and colleagues presented with this diagnosis.
Th e authors went on to investigate the prognosis value of urinary sTREM-1 concentration and found that, in comparison with survivors, non-survivors exhibited a permanent increase of sTREM-1. Again, the plasma level of sTREM-1 has been repeatedly associated with prognosis or severity: the current study shows that its urinary measurement may also be interesting in this context. Th e major fi nding of Su and colleagues is that urinary sTREM-1 measurement is able to predict the development of sepsis-associated acute kidney injury (AKI). Indeed, when sTREM-1 was measured within 48 hours before the diagnosis of AKI, its elevation was associated with a 94% sensitivity and a 76% specifi city in predicting the occurrence of this condition. Th is is the fi rst report showing that sTREM-1 may predict AKI.
Th is poses several questions. First, where does urinary sTREM-1 originate from? Measured in the urine, sTREM-1 may refl ect a systemic production and may correlate with its plasma concentration: as sTREM-1 is a 27-kDa protein, it can be excreted by the kidney provided that kidney injury exists. But sTREM-1 could also be
Abstract
The triggering receptor expressed on myeloid cells-1 (TREM-1) is an immunoreceptor whose role is to amplify the infl ammatory response mediated by the engagement of Toll-like and NOD-like receptors. As the expression of TREM-1 is believed to be upregulated during infection, this protein has been studied as a sepsis biomarker. In the previous issue of Critical Care, Su and colleagues reported on the usefulness of urinary soluble TREM-1 in diagnosing sepsis and assessingits severity. Importantly, the authors describe, for the fi rst time, that urinary soluble TREM-1 measurement is able to predict the development of sepsis-associated acute kidney injury (AKI). If these results were to be confi rmed by larger studies, urinary soluble TREM-1 would possibly become a new biomarker for sepsis-associated AKI. produced locally by the endothelial cells or the infi ltrating infl ammatory cells that are recruited during acute tubular necrosis or both. Unfortunately, the plasma concen trations of sTREM-1 are not described in the current study and therefore it is impossible to draw any conclusions regarding the origin of urinary sTREM-1 during AKI.
Several other biomarkers have been investigated for the diagnosis of sepsis-associated AKI. Th e measurement of plasma neutrophil gelatinase-associated lipocalin (NGAL), for example, was able to predict AKI progression during sepsis with an acceptable performance [11] . Th erefore, it would be interesting to compare the sTREM-1 performance with that of these other markers. Finally, as underlined by the authors, only 17 out of 88 patients with sepsis developed an AKI after 48 hours of admission. Th is very low sample size warrants caution in interpreting the results of the study, and confi rmatory work is needed.
In their study, Su and colleagues confi rm the usefulness of measuring sTREM-1 concentration in diagnosing sepsis and assessing its severity. Th ey also extend the current knowledge on TREM-1 in showing that its soluble form, when measured in the urine, was able to predict the development of AKI. If these results were to be confi rmed by larger studies, urinary sTREM-1 would possibly become a new bio marker for sepsis-associated AKI.
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